研究单位：[1]Biotech Pharmaceutical Co.,Ltd.[2]The Third People's Hospital of Zhengzhou Zhengzhou,Henan,China[3]Xiangya Hospital of Centre-south University Changsha,Hunan,China[4]West China Hospital,Sichuan University Chengdu,Sichuan,China[5]Beijing Tiantan Hospital,Capital Medical University Beijing,China[6]Peking Union Medical College Hospital Beijing,China[7]Xuanwu Hospital Capital Medical University Beijing,China[8]Shandong Cancer Hospital Jinan,China[9]Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine Shanghai,China
研究目的：
This is a prospective, open-label, single arm, multicenter clinical study. The purpose of the study is to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent radiochemotherapy in children with newly diagnosed diffuse intrinsic pontine glioma(DIPG).
